Adcentrx Therapeutics Expands Clinical Trial for Cancer Treatment with China NMPA Clearance
Adcentrx Therapeutics has received clearance from the China National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for ADRX-0405, an Antibody-Drug Conjugate (ADC) targeting late-stage solid tumors, including prostate cancer. This clearance allows Adcentrx to include clinical centers in China in its ongoing Phase 1a/1b trial, which is already underway in the U.S. ADRX-0405 targets the STEAP1 protein, overexpressed in certain cancers, and aims to address unmet medical needs across multiple tumor types. The trial will assess the safety, tolerability, and optimal dosing of ADRX-0405, with completion of the Phase 1a portion expected by the end of 2026. 
